Is This Trillion-Dollar Industry on the Verge of Collapse?

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Cannabis Profits Daily. If you have any questions or would like to change free your email settings, please reference the contact information at the bottom of this email.

Thursday, January 31, 2019 Avoid Losing Your Shirt When Big Pharma Takes On Cannabis By Greg Miller The cannabis plant offers tremendous potential as a natural pain reliever. The active compounds contained within cannabis plants are incredibly effective and - in most cases - easily made into treatments. Sensing a profit opportunity, Big Pharma is trying to enter the game. In fact, 7 of Canada's top 10 cannabis holders are major pharmaceutical companies. Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) are leading cannabis patent holders in Canada, according to a joint research report from analytics firm New Frontier Data and UK-based cannabis company Grow Biotech. But here at the National Institute for Cannabis Investors, we believe pharmaceutical companies will have a hard time turning these treatments into profitable drugs. Of course, that's not stopping many drug companies from trying to shoe-horn these old approaches into their development of cannabis-based medications. For decades, pharmaceutical companies have controlled the medical industry with lab-created drugs. They haven't even considered offering a more natural solution. Now, with an opioid crisis devastating communities around the U.S., the chickens have come home to roost. People do not want to become addicted to Oxycodone, and they are turning to cannabis-based medicines to fight anxiety, depression, and physical pain. Because they ignored medical marijuana for so long, pharmaceutical companies could rack up hundreds of millions - or even billions - in losses for investors. Patients could ultimately decide they would rather not pay the huge premiums that come with certain prescription drugs, and they certainly don't want to buy medicine that could lead to addiction. Before you invest in a pharmaceutical company claiming to be developing the next "blockbuster cannabis drug," you need to understand the company's profit model. The old methods pharmaceutical companies have relied on won't work for cannabis-based medicines. We're here to tell you how not to lose your shirt when Big Pharma jumps into the cannabis world... The Best Stock Screener Every Cannabis Investor Should Be Using These are the Next Cannabis IPOs That Could Make You Rich Why 2019 Could Be the Biggest Year for Cannabis Yet Our Latest Runaway Pot Stock Recommendation Just Went Live! Our team of analysts just released our latest cannabis IPO play. And I've got to say, the upside potential that's packed into this under-the-radar cannabis stock is incredible. Right now, this revolutionary cannabis grower is trading for less than $7 a share. But don't expect that discounted price to stick around for long. As soon as the market wakes up to the incredible opportunity lurking in this micro-cap stock, it could start surging into double-digit, even triple-digit gain territory virtually overnight. Given the scope of the moneymaking potential in store, you're definitely going to want to check this out. All you have to do is click here for all of the details. Did you know that there could be a million-dollar profit opportunity in cannabis... if you know where to look? Fact is, cannabis prohibition is quickly becoming a thing of the past. But within this million-dollar opportunity also lies nearly a million different hitters in the game - making it nearly impossible to identify the winners from the wannabes. That's why we've done the heavy lifting for you - and narrowed it down to four pot stocks with MASSIVE upward potential. Just click the link below to find out how to access them for yourself. You are receiving this e-mail at its028@gmail.com, as a part of your subscription. Remove your email from this list: Unsubscribe © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 Contact Customer Service Website: https://nicinvestors.com Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. Privacy Policy | Terms & Conditions